Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 577Triple Negative Breast Neoplasms 125Neoplasm Metastasis 50Breast Neoplasms, Male 28Ovarian Neoplasms 26Neoplasms 26Inflammatory Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 19Stomach Neoplasms 14Endometrial Neoplasms 11Carcinoma, Ductal, Breast 11Carcinoma, Ovarian Epithelial 10Pancreatic Neoplasms 9Colorectal Neoplasms 9Melanoma 8Lung Neoplasms 8HER2-positive Breast Cancer 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Squamous Cell Carcinoma of Head and Neck 6Prostatic Neoplasms 6Esophageal Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 4Brain Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Advanced Breast Cancer 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3

Interventions

exemestane 1Paclitaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
First Line Metastatic Breast Cancer × Paclitaxel × Breast × Clear all
NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

ARCAGY/ GINECO GROUP

Phase 3 Terminated
117 enrolled
Breast

First Line Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡